
Humana (HUM) Stock Forecast & Price Target
Humana (HUM) Analyst Ratings
Bulls say
Humana's financial outlook is bolstered by an increased 2025 EPS estimate of $17.06, reflecting strong second-quarter results and updated guidance. The company anticipates year-over-year earnings growth in 2027, supported by effective margin initiatives, despite stable performance in its Stars program. Additionally, Humana’s superior Medicare Advantage star rating positions the company favorably amidst evolving regulatory and reimbursement landscapes, reinforcing its competitive advantage in the market.
Bears say
The financial outlook for Humana indicates potential challenges, with management projecting a slight decline in earnings per share (EPS) for 2026 compared to 2025, primarily due to headwinds related to Medicare Star ratings. The company faces a variety of downside risks, including increased competition in Medicare Advantage, inadequate reimbursement rates, and declining membership in its Prescription Drug Plans, all of which could adversely affect future growth. Additionally, estimates for FY27 EPS have been conservatively adjusted, anticipating a shortfall of approximately 10% driven by increased investment aimed at recovering Star ratings performance.
This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.
Humana (HUM) Analyst Forecast & Price Prediction
Start investing in Humana (HUM)
Order type
Buy in
Order amount
Est. shares
0 shares